# An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

> **NCT01026376** · — · NO_LONGER_AVAILABLE · sponsor: **Janssen-Cilag Farmaceutica Ltda.**

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** decitabine
- **DRUG:** decitabine

## Key facts

- **NCT ID:** NCT01026376
- **Lead sponsor:** Janssen-Cilag Farmaceutica Ltda.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** 2008-06
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** — (—)
- **Last updated:** 2013-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01026376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01026376, "An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01026376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*